489 related articles for article (PubMed ID: 28160873)
1. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
[TBL] [Abstract][Full Text] [Related]
2. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG
J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372
[TBL] [Abstract][Full Text] [Related]
3. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
[TBL] [Abstract][Full Text] [Related]
4. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
[TBL] [Abstract][Full Text] [Related]
5. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
6. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK
J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Le QA; Hay JW; Becker R; Wang Y
Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
[TBL] [Abstract][Full Text] [Related]
8. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
[TBL] [Abstract][Full Text] [Related]
9. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.
Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
Semin Arthritis Rheum; 2020 Jun; 50(3):394-400. PubMed ID: 32160943
[TBL] [Abstract][Full Text] [Related]
12. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
Reginster JY; Al Daghri N; Kaufman JM; Bruyère O
Expert Opin Pharmacother; 2018 Feb; 19(2):159-161. PubMed ID: 29251010
[TBL] [Abstract][Full Text] [Related]
13. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
[TBL] [Abstract][Full Text] [Related]
14. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
[TBL] [Abstract][Full Text] [Related]
15. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
16. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
[TBL] [Abstract][Full Text] [Related]
17. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Greenspan SL; Fitzpatrick LA; Mitlak B; Wang Y; Harvey NC; Deal C; Cosman F; McClung M
Menopause; 2020 Oct; 27(10):1137-1142. PubMed ID: 32665529
[TBL] [Abstract][Full Text] [Related]
18. Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).
Winzenrieth R; Kostenuik P; Boxberger J; Wang Y; Humbert L
JBMR Plus; 2022 Apr; 6(4):e10612. PubMed ID: 35434451
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
